Form 4: CytomX Therapeutics CFO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Christopher Ogden, CFO of CytomX Therapeutics, sold 8,551 shares of common stock on March 18, 2025, to cover tax obligations related to vesting restricted stock units.
Summary
- On March 18, 2025, Christopher Ogden, the Chief Financial Officer of CytomX Therapeutics, sold 8,551 shares of the company's common stock.
- The sale was executed at a price of $0.599 per share.
- This transaction was conducted to satisfy tax or other government withholding obligations associated with the vesting of restricted stock units (RSUs).
- Following the transaction, Ogden directly owns 201,026 shares, which includes 155,821 RSUs.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sale of shares to cover tax obligations) and does not contain any information that would significantly impact investor sentiment positively or negatively.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives.
Key Dates
| Date | Description |
|---|---|
| 03/18/2025 | Date of the transaction: Christopher Ogden sold shares of CytomX Therapeutics common stock. |
| 03/20/2025 | Date of signature on the Form 4 filing. |
Keywords
CytomX Therapeutics, Christopher Ogden, CTMX, Form 4, Share Sale, CFO, Restricted Stock Units, RSUs, Tax Obligations
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.